Neo Ivy Capital Management bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) during the fourth quarter, HoldingsChannel.com reports. The firm bought 16,386 shares of the biotechnology company’s stock, valued at approximately $188,000. Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) Director Machelle Sanders sold 4,000 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $7.98, for a total value of $31,920.00. Following the sale, the director now owns 25,611 shares in the company, valued at approximately […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 35,580,000 shares, an increase of 10.2% from the May 15th total of 32,300,000 shares. Based on an average daily trading volume, of 2,730,000 shares, the days-to-cover ratio […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) saw a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 35,580,000 shares, a growth of 10.2% from the May 15th total of 32,300,000 shares. Based on an average daily volume of 2,730,000 shares, the short-interest ratio is […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) Director Machelle Sanders sold 4,000 shares of the stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $7.98, for a total transaction of $31,920.00. Following the transaction, the director now directly owns 25,611 shares of the company’s stock, […]